These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3107626)

  • 1. Correlation between inhibitory effect on platelet aggregation and disposition of sulfinpyrazone and its metabolites in rabbits. Part I: Single dose study.
    Ritschel WA; Kuo BS
    Biopharm Drug Dispos; 1987; 8(1):1-9. PubMed ID: 3107626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between inhibitory effect on platelet aggregation and disposition of sulfinpyrazone and its metabolites in rabbits. Part II: Multiple dose study.
    Kuo BS; Ritschel WA
    Biopharm Drug Dispos; 1987; 8(1):11-21. PubMed ID: 3580509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing.
    Pedersen AK; FitzGerald GA
    Clin Pharmacol Ther; 1985 Jan; 37(1):36-42. PubMed ID: 3917387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human platelet cyclo-oxygenase activity by sulfinpyrazone and three of its metabolites.
    Del Maschio A; Livio M; Cerletti C; De Gaetano G
    Eur J Pharmacol; 1984 Jun; 101(3-4):209-14. PubMed ID: 6432556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.
    Rosenkranz B; Fischer C; Jakobsen P; Kirstein Pedersen A; Frölich JC
    Eur J Clin Pharmacol; 1983; 24(2):231-5. PubMed ID: 6840173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of the relationship between ex vivo and in vivo effects of sulphinpyrazone in the guinea pig.
    Butler KD; Wallis RB; White AM
    Haemostasis; 1979; 8(3-5):353-60. PubMed ID: 159853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New metabolites of sulfinpyrazone in man.
    Dieterle W; Faigle JW; Moppert J
    Arzneimittelforschung; 1980; 30(6):989-93. PubMed ID: 7191279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged inhibition of ex vivo sodium arachidonate-induced platelet aggregation and malondialdehyde (MDA) production by sulphinpyrazone (Anturan) in man.
    Maguire ED; Pay GF; Wallis RB; White AM
    Thromb Res; 1981 Feb; 21(3):321-7. PubMed ID: 7245142
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of sulfinpyrazone and its metabolite G25671 on platelet activation and desensitization and on bronchoconstriction induced by the prostaglandin endoperoxide analog U46619.
    Hatmi M; del Maschio A; Lefort J; de gaetano G; Vargaftig BB; Cerletti C
    J Pharmacol Exp Ther; 1987 May; 241(2):623-7. PubMed ID: 3106620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo.
    Pay GF; Wallis RB; Zelaschi D
    Haemostasis; 1981; 10(3):165-75. PubMed ID: 7262645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prolonged effect of sulfinpyrazone on collagen-induced platelet aggregation in vivo.
    Buchanan MR; Rosenfeld J; Hirsh J
    Thromb Res; 1978 Nov; 13(5):883-92. PubMed ID: 741458
    [No Abstract]   [Full Text] [Related]  

  • 12. A metabolite of sulphinpyrazone that is largely responsible for the effect of the drug on the platelet prostaglandin pathway.
    Pay GF; Wallis RB; Zelaschi D
    Biochem Soc Trans; 1980 Dec; 8(6):727-8. PubMed ID: 7461266
    [No Abstract]   [Full Text] [Related]  

  • 13. Species differences in the disposition and metabolism of sulfinpyrazone.
    Dieterle W; Faigle JW
    Xenobiotica; 1981 Aug; 11(8):559-68. PubMed ID: 7303725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of two different dosage regimens of sulphinpyrazone on platelet function ex vivo and blood chemistry in man.
    Maguire ED; Pay GF; Turney J; Wallis RB; Weston MJ; White AM; Williams LC; Woods HF
    Haemostasis; 1981; 10(3):153-64. PubMed ID: 7262644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of very low versus standard dose acetyl salicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man.
    Lorenz R; Siess W; Weber PC
    Eur J Pharmacol; 1981 Apr; 70(4):511-8. PubMed ID: 7238575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulphinpyrazone inhibits platelet function and enhances blood fibrinolytic activity in the rat.
    Hussaini IM; Moore PK
    Thromb Res; 1988 Nov; 52(4):337-41. PubMed ID: 3201405
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics and reversible biotransformation of sulfinpyrazone and its metabolites in rabbits. I. Single-dose study.
    Ritschel WA
    Pharm Res; 1986 Jun; 3(3):173-7. PubMed ID: 24271525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of orally administered sulphinpyrazone (Anturan) on platelet aggregation in vitro.
    Pfister B; Godbillon J; Colussi D; Imhof P
    Thromb Res; 1980 Apr 1-15; 18(1-2):89-99. PubMed ID: 7404507
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins.
    Chang WC; Hsu FL
    Prostaglandins Leukot Essent Fatty Acids; 1989 Dec; 38(3):181-8. PubMed ID: 2516322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of acetylsalicylic acid, sulfinpyrazone and their combination on collagen-induced platelet aggregation in guinea pigs.
    Wong LT; Zawidzka Z; Thomas BH
    Pharmacol Res Commun; 1978 Nov; 10(10):939-49. PubMed ID: 733865
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.